阿托伐他汀钙联合依那普利治疗高血压合并冠状动脉粥样硬化性心脏病的效果

Effects of Atorvastatin calcium combined with Enalapril on hypertension and coronary atherosclerotic heart disease

目的:观察阿托伐他汀钙联合依那普利治疗高血压合并冠状动脉粥样硬化性心脏病(冠心病)患者的临床效果。方法:选取收治的157例高血压合并冠心病患者的临床资料,根据治疗方式不同分为对照组(75例)和观察组(82例)。对照组采取依那普利治疗,观察组在对照组基础上联合阿托伐他汀钙治疗。比较两组患者临床疗效,血压、血脂水平及不良反应发生率。结果:观察组临床总有效率为87.80%,高于对照组的73.33%,差异有统计学意义(P<0.05);治疗后,观察组收缩压、舒张压、三酰甘油、总胆固醇水平均低于对照组,差异有统计学意义(P<0.05);观察组和对照组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀钙联合依那普利治疗高血压合并冠心病效果较好,可促进患者血压、血脂恢复至正常水平,且不良反应较少,安全性较高。

Objective:To observe clinical effects of Atorvastatin calcium combined with Enalapril in treatment of patients with hypertension and coronary atherosclerotic heart disease.Methods:The clinical data of 157 patients with hypertension and coronary heart disease admitted to our hospital from December 2015 to February 2018 were retrospectively analyzed.According to different treatment methods,they were divided into control group(75 cases)and observation group(82 cases).The control group was treated with Enalapril,while the observation group was treated with Atorvastatin calcium on the basis of that of the control group.The clinical efficacy,blood pressure,blood lipid levels and incidence of adverse reactions were compared between the two groups.Results:The total clinical effective rate of the observation group was 87.80%,which was higher than that of the control group(73.33%),and the difference was statistically significant(P<0.05).After the treatment,the systolic blood pressure,diastolic blood pressure,triglyceride and total cholesterol levels in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusions:Atorvastatin calcium combined with Enalapril is effective in the treatment of the patients with hypertension and coronary heart disease.It can promote the recovery of blood pressure and blood lipids to the normal levels with fewer adverse reactions and higher safety.